The Expression of ERβcx in Human Breast Cancer and the Relationship to Endocrine Therapy and Survival

Purpose: Estrogen receptor (ER) α-positive breast cancer is often treated with endocrine therapy using either antiestrogens or aromatase inhibitors. However, 30% of patients who receive endocrine therapy will derive no benefit from such treatments and may indeed suffer adverse effects. Currently, there are no ways to predict response to such treatments. ERβcx, a variant of ERβ, has a dominant-negative effect over ERα, and its expression thought to modulate response to endocrine treatment may represent a predictor of response to endocrine therapy. Experimental Design: We investigated the expression of the ERβcx in 82 frozen breast samples (8 benign, 1 ductal carcinoma in situ, and 73 malignant) by Western blot analysis. The relationship between the expression of ERβcx variants with prognosis and outcome of endocrine therapy was examined. Results: There was a statistically significant association between the presence of ERβcx and the response to endocrine therapy (Fisher’s exact test, P = 0.04). We also examined the influence of the ERβcx status of a tumor on time to progression and death. There was a relationship between the presence of ERβcx and survival, with patients whose tumors express ERβcx having a longer survival rate (P = 0.05). Cell-type specificity of expression was assessed by immunohistochemistry on a selection of histological samples. Conclusions: On the basis of this small group of patients, we conclude that the expression of ERβcx correlated with favorable response to endocrine therapy. A larger study involving the staining of archival material is currently underway to confirm these preliminary results.

[1]  C. Osborne,et al.  Steroid hormone receptors in breast cancer management , 2004, Breast Cancer Research and Treatment.

[2]  P. Saunders,et al.  Human oestrogen receptors: differential expression of ERalpha and beta and the identification of ERbeta variants , 2002, Steroids.

[3]  J. Gustafsson,et al.  Expression of Estrogen Receptor (ER) βcx Protein in ERα-positive Breast Cancer: Specific Correlation with Progesterone Receptor , 2002 .

[4]  I. Leav,et al.  Expression of estrogen receptor beta in the fetal, neonatal, and prepubertal human prostate , 2002, The Prostate.

[5]  Jessy Abraham,et al.  Identification of ten exon deleted ERβ mRNAs in human ovary, breast, uterus and bone tissues: alternate splicing pattern of estrogen receptor β mRNA is distinct from that of estrogen receptor α , 2002 .

[6]  R C Coombes,et al.  Estrogen receptor beta in breast cancer. , 2002, Endocrine-related cancer.

[7]  Simak Ali,et al.  Endocrine-responsive breast cancer and strategies for combating resistance , 2002, Nature Reviews Cancer.

[8]  Christine Solbach,et al.  Identification of high risk breast-cancer patients by gene expression profiling , 2002, The Lancet.

[9]  S. Inoue,et al.  Evaluation of oestrogen receptor beta wild-type and variant protein expression, and relationship with clinicopathological factors in breast cancers. , 2002, European journal of cancer.

[10]  R. Coombes,et al.  Estrogen receptors and proliferation markers in primary and recurrent breast cancer , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[11]  M. Murai,et al.  Expression of Estrogen Receptor (ER–α and ER–β) mRNA in Human Prostate Cancer , 2001, European Urology.

[12]  T. Karn,et al.  Molecular classification of breast cancer patients by gene expression profiling * , 2001, The Journal of pathology.

[13]  J. Gustafsson,et al.  Decreased expression of estrogen receptor beta protein in proliferative preinvasive mammary tumors. , 2001, Cancer research.

[14]  B. Shoker.  Estrogen receptor β in breast cancer , 2000, Breast Cancer Research.

[15]  Helmut Dotzlaw,et al.  Functional characteristics of a novel murine estrogen receptor-beta isoform, estrogen receptor-beta 2. , 2000, Journal of molecular endocrinology.

[16]  N. Lorenzon,et al.  Differential expression of estrogen receptor beta splice variants in rat brain: identification and characterization of a novel variant missing exon 4. , 2000, Brain research. Molecular brain research.

[17]  D Barnes,et al.  Immunohistochemical detection of steroid receptors in breast cancer: a working protocol , 2000, Journal of clinical pathology.

[18]  R. Handa,et al.  Expression of estrogen receptor-beta protein and mRNA in the cerebellum of the rat , 2000, Neuroscience Letters.

[19]  V. Speirs,et al.  Identification of wild-type and exon 5 deletion variants of estrogen receptor beta in normal human mammary gland. , 2000, The Journal of clinical endocrinology and metabolism.

[20]  M. van Glabbeke,et al.  New guidelines to evaluate the response to treatment in solid tumors , 2000, Journal of the National Cancer Institute.

[21]  H. Magdelenat.  The Receptor and Biomarker Study Group of the EORTC , 2000 .

[22]  Jorma Isola,et al.  Estrogen Receptor β Is Coexpressed with ERα and PR and Associated with Nodal Status, Grade, and Proliferation Rate in Breast Cancer , 2000 .

[23]  M Van Glabbeke,et al.  New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. , 2000, Journal of the National Cancer Institute.

[24]  Helmut Dotzlaw,et al.  Functional characteristics of a novel murine estrogen receptor- isoform, estrogen receptor- 2 , 2000 .

[25]  M. Kerin,et al.  Increased expression of estrogen receptor beta mRNA in tamoxifen-resistant breast cancer patients. , 1999, Cancer research.

[26]  C K Osborne,et al.  Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[27]  V. Giguère,et al.  Dominant Activity of Activation Function 1 (AF-1) and Differential Stoichiometric Requirements for AF-1 and -2 in the Estrogen Receptor α-β Heterodimeric Complex , 1999, Molecular and Cellular Biology.

[28]  Mike Clarke,et al.  Polychemotherapy for early breast cancer: an overview of the randomised trials , 1998, The Lancet.

[29]  P. T. Saunders,et al.  Oestrogen receptor beta (ER beta). , 1998, Reviews of reproduction.

[30]  Y. Ouchi,et al.  Molecular cloning and characterization of human estrogen receptor βcx: A potential inhibitor of estrogen action in human , 1998 .

[31]  L. Murphy,et al.  Altered Estrogen Receptor α and β Messenger RNA Expression during Human Breast Tumorigenesis , 1998 .

[32]  J. Lehmann,et al.  Cloning and Characterization of Human Estrogen Receptor β Isoforms , 1998 .

[33]  Mike Clarke,et al.  Tamoxifen for early breast cancer: an overview of the randomised trials , 1998, The Lancet.

[34]  Helmut Dotzlaw,et al.  Estrogen receptor-β mRNA variants in human and murine tissues , 1998, Molecular and Cellular Endocrinology.

[35]  P. Koza-Taylor,et al.  Identification of Estrogen Receptor β2, A Functional Variant of Estrogen Receptor β Expressed in Normal Rat Tissues. , 1998, Endocrinology.

[36]  Y. Ouchi,et al.  Cross‐inhibition of both estrogen receptor α and β pathways by each dominant negative mutant , 1998 .

[37]  Y. Ouchi,et al.  The complete primary structure of human estrogen receptor beta (hER beta) and its heterodimerization with ER alpha in vivo and in vitro. , 1998, Biochemical and biophysical research communications.

[38]  J. Klijn,et al.  The prognostic value and relationships of patient characteristics, estrogen and progestin receptors, and site of relapse in primary breast cancer , 1988, Cancer.

[39]  W. McGuire,et al.  Steroid hormone receptors in the management of human breast cancer. , 1980, Annals of clinical research.

[40]  W. McGuire,et al.  Hormone receptors in primary and advanced breast cancer. , 1980, Clinics in endocrinology and metabolism.